The first trading day of July (July 2nd) for Hong Kong stocks saw the healthcare sector surge again, with innovative drug stocks leading the entire market! The HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880), which focuses 100% on innovative drug R&D, touched an intraday high of 5.43%. Another ETF with over 45% exposure to CXO companies also rose significantly.
Focusing on Hong Kong Stock Connect innovative drug stocks, the market opened with strong momentum, with over ten stocks including IMMUNOTECH-B (06978) rising by more than 10%. Although the pace of gains moderated in the afternoon, the sector remained significantly stronger than the broader market. Major heavyweight stocks posted solid gains.
The HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) closed up 3.7% on heavy volume, with daily turnover reaching a near three-month high. The fund manager has previously suggested that from a medium-term perspective, the current price level for innovative drugs may offer significant potential for upside.
What Recent Market Moves Signal
The healthcare sector in Hong Kong has seen two significant rallies in the last three trading sessions, with Hong Kong Stock Connect innovative drug stocks showing particularly strong momentum. This breakout from a low-price range on high volume is sending a clear signal. Some analysts believe that a combination of fundamental factors is supporting a potential bottoming and recovery for the innovative drug sector. The window for a re-rating of core leading companies may have arrived, with ample room for valuation expansion.
Supportive News and Catalysts
Recently, there has been a series of positive developments for innovative drugs. On the policy front, negotiations for a dual "insurance + commercial insurance" reimbursement catalog are progressing, with new mechanisms such as pre-application and eight-year price protection being implemented, further improving the payment system for innovative drugs. On the industry side, a significant number of listed pharmaceutical companies have conducted share buybacks this year, reflecting confidence. Furthermore, the upcoming interim earnings season in July could serve as an important catalyst.
Positive Influence from Overseas Markets
Overseas markets are also providing support. Despite lingering market concerns about the Federal Reserve's interest rate policy weighing on growth sectors, the XBI Index, a global bellwether for biotech, has shown independent strength, surging significantly over recent periods.
Institutional Perspective on Trading Opportunities
From a market trading perspective, some securities firms see considerable opportunity in Hong Kong Stock Connect innovative drug stocks. The logic is twofold: first, the overall quality of the constituent companies is excellent; second, the current tech bull market is global in nature, and if it enters a period of volatility, funds flowing back to Hong Kong markets from regions like Japan and South Korea are likely to favor innovative drug stocks as a primary allocation choice.
Key Investment Vehicles to Consider
To capture the rebound opportunity in Hong Kong Stock Connect healthcare, investors can focus on two key T+0 trading tools. For a pure-play exposure to innovative drug R&D companies, one specific ETF is highlighted. For exposure across the broader innovative drug industry chain, including CXO companies, another ETF provides targeted access.
Investors should note that ETFs do not charge sales service fees. Brokerage commissions may apply for subscriptions and redemptions. Detailed fund fee structures are available in the respective legal documents. All data is sourced from relevant stock exchanges and index providers.
Important Risk Disclosures
The mention of index constituents is for illustrative purposes only and does not constitute investment advice or indicate the holdings of any specific fund. The risk rating for the mentioned ETFs and their feeder funds is R4 (medium to high risk), suitable for aggressive (C4) and above investors. Any information presented is for reference only, and investors are responsible for their own investment decisions. Past performance of any fund is not a guarantee of future results. Fund investment carries risks.